Marceline Clementine Appointed Chief Financial Officer
News Sep 19, 2012
Trophos SA has announced the appointment of Marceline Clementine as chief financial officer.
Marceline Clementine has more than 30 years experience in the world of finance. She joined Trophos in 2006 as administration and finance manager.
Before that, she had worked as chief accountant or financial controller at various companies in the real estate and catering sectors, including Groupe FLO.
She is now responsible for all administrative and financial services at Trophos, as well as for human resources management.
Marceline Clementine succeeds Christine Placet, the former chief financial officer, who has just been promoted to the post of chief executive officer of Trophos.
“We are delighted to welcome Marceline Clementine as chief financial officer,” said Christine Placet, the CEO of Trophos.
Placet continued, “This appointment is a recognition of Ms. Clementine’s competence in financial matters and her strong commitment to Trophos over the past few years. Her financial management skills are a precious asset for the company. We are continuing our quest to find strategic partners for our current programs to guarantee the future of our company, which was founded 13 years ago now.”
Trophos has sufficient funding in hand to continue its research activities up to 2014.
The company is currently undertaking several programs focused on the following drug candidates:
• Olesoxime in Spinal Muscular Atrophy (SMA): a pivotal study is underway and the results are expected in the second half of 2013.
• Olesoxime for multiple sclerosis (MS) disease progression: a phase II proof-of-concept study has been designed in conjunction with international MS specialists.
• TRO40303 cardiac protection compound: a phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI) is underway and the results are expected in the first half of 2013.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE